GLP-1 receptor distribution: central and peripheral — one year on

GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable.

A documentation question rather than an analytical one.

I have a certificate in front of me that reports a purity figure, names a technique, gives a wavelength, and stops. No gradient, no column, no injection volume, no chromatogram.

What can I legitimately conclude from that document? My instinct is "almost nothing, but not literally nothing", and I would like to know where the people who read these professionally draw the line.

the opening post is right about the mechanism and I think understates the practical bit.

GIP receptor signalling: the glucose-dependent insulinotropic peptide receptor (GIP) is involved in glucose-stimulated insulin secretion. GIP agonism is thought to contribute to tirzepatide's effect but the mechanism is not fully settled.

Species differences: rodent studies show the same compounds produce effects in rodents that predict human effects reasonably well for semaglutide and tirzepatide. The track record is less clear for novel compounds with less human data.

Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ between compounds are usually about potency or receptor selectivity.

Cross-reactivity and selectivity: the compounds are not perfectly selective for their target receptors. Semaglutide has some activity on other receptors; tirzepatide activates both GLP-1 and GIP with different affinities. The off-target effects are part of the overall pharmacology.